Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to evaluate the safety and tolerability of
suprachoroidal microcatheterization with the Oxulumis® device for a randomized treatment with
two dose levels of Triesence® in subjects with Diabetic Macular Edema.